A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00737256
Verified September 2012 by Paul Saenger, Denver Research Institute. Recruitment status was: Recruiting
The purpose of this study is to gather systematic clinical data on whether aripiprazole, a partial dopamine agonist, beneficially affects schizophrenia plus cocaine dependence subjects. Since aripiprazole has established effects against schizophrenia, the study focuses on whether aripiprazole concurrently reduces co-morbid cocaine dependence in schizophrenia plus cocaine dependence sufferers compared to a standard typical antipsychotic treatment (perphenazine). The working hypothesis states that subjects in the aripiprazole treatment arm of the study will give fewer cocaine positive urine specimens as compared to the perphenazine control arm.
The proportion of negative urine drug screen results will be significantly greater in the subjects treated with aripiprazole than in those treated with perphenazine. [ Time Frame: Week 3 and Week 8 of study participation ]
Secondary Outcome Measures
The mean total self-report cocaine use days will be significantly fewer in subjects treated with aripiprazole than in those treated with perphenazine. [ Time Frame: End of study participation ]
The mean cocaine craving scores will be lower in subjects treated with aripiprazole than in those treated with perphenazine. [ Time Frame: End of study participation ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Have a primary DSM-IV diagnosis of Schizophrenia or Schizoaffective disorder
Have a DSM-IV diagnosis of current cocaine dependence.
Are capable of reading, comprehending, and signing informed consent.
Agree to take Aripiprazole or Perphenazine as treatment for SCHZ and CD.
Agree to stop taking any other antipsychotic medication
If female and of child bearing potential (WOCBP) agree to use an acceptable form of birth control and have a negative pregnancy test within 2 days prior to starting study medication
Under 18 years old or over 65 years old.
Refusal or inability to give informed consent,
Have a history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities, cerebrovascular disease, or conditions that would predispose to hypotension (dehydration, hypovolemia),
A history of seizures or conditions that lower the seizure threshold
Have current suicidal ideation (history of suicide attempt in past 60 days)
Are actively psychotic which in the opinion of the investigator would preclude proper informed consenting or protocol adherence
Are receiving or plan to receive an agent metabolized by the Cytochrome P450-3A4 or -2D6 systems, including carbamazepine, ketoconazole, quinidine, fluoxetine, and paroxetine
WOCBP not on, or do not agree to use an acceptable form of contraception
Known sensitivity to aripiprazole or perphenazine
A diagnosis of current or past tardive dyskinesia
Pending legal charges or a court mandate for drug treatment
Currently taking concomitant medications that have been shown to reduce cocaine use, such as disulfiram
Clinically significant liver function abnormalities